Sign In
Buy CRDF
$1.40
-0.110 (-7.28%)
At Close: Jun 03, 2026
Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives $10.63 Average Price Target from Analysts
01:04am, Tuesday, 25'th Nov 2025
Shares of Cardiff Oncology, Inc. (NASDAQ: CRDF - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six brokerages that are presently covering the firm, MarketBe
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference
07:00am, Monday, 24'th Nov 2025
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update
04:05pm, Thursday, 06'th Nov 2025
– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects t
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
04:01pm, Tuesday, 04'th Nov 2025
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance
Cardiff Oncology: Preparing For A Defining 2026
07:50am, Saturday, 25'th Oct 2025
Cardiff Oncology is a speculative buy, driven by the potential of onvansertib as a first-in-class PLK1 inhibitor for first-line RAS-mutated mCRC. CRDF's Q1 2026 data readout for onvansertib is a pivot
Cardiff Oncology's Promising Cancer Breakthrough Ahead - Why I Choose To Buy
07:45am, Wednesday, 22'nd Oct 2025
Cardiff Oncology receives a 'Buy' rating, driven by promising clinical data and strategic leadership for long-term investors. CRDF's lead candidate, onvansertib, shows strong efficacy and safety in Ph
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
04:05pm, Thursday, 02'nd Oct 2025
SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
04:05pm, Thursday, 28'th Aug 2025
SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cance
Cardiff Oncology (CRDF) Q2 Loss Down 19%
05:50pm, Wednesday, 30'th Jul 2025
Cardiff Oncology (CRDF) Q2 Loss Down 19%
Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?
03:27pm, Wednesday, 30'th Jul 2025
As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff Oncolo
Cardiff Oncology: Data Update Resolves Some Signals
11:32am, Wednesday, 30'th Jul 2025
Onvansertib continues to show dose-dependent activity in KRAS-mutated mCRC, with response rates improving up to 49% in the high-dose arm. Recent data are less dramatic than early interim results, refl
Cardiff Oncology (CRDF) Reports Q2 Loss, Lags Revenue Estimates
06:26pm, Tuesday, 29'th Jul 2025
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.26 per share a year ago.
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
04:07pm, Tuesday, 29'th Jul 2025
– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) –
Cardiff Oncology: Delayed Trial Data Update Unnerves Investors But Gives Bulls A Final Buy Low Opportunity
08:30am, Friday, 27'th Jun 2025
Cardiff Oncology's recent trial data readout delay has unnerved the market, but I see this as a potential buying opportunity for speculative investors. Leadership change is not a major risk factor. Th
Cardiff Oncology Names Roger Sidhu as Medical Chief
04:39pm, Tuesday, 17'th Jun 2025
Sidhu joined Cardiff from Treadwell Therapeutics, where he was medical chief and acting chief executive officer. Previously, Sidhu spent nearly 10 years at Amgen.
